pipette
ENEnglish

Response-Adapted Postoperative Therapy Following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: a phase II trial

Yu Qian, 胡柳, Liang Jiang, Manxiang Wang, Xin Jin, Wenyou Deng, Kun Wu, Shuang Qin, Desheng Hu, Jian Chen, Yuan Wu

Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Neoadjuvant chemo-immunotherapy (NACI) demonstrates promising efficacy in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), yet its effect on postoperative radiotherapy/chemoradiotherapy (PORT/POCRT) remains undefined. This open-label phase 2 study (NCT05476965) assessed NACI efficacy and its role in guiding adaptive PORT/POCRT. Primary endpoint was major pathologic response (MPR) rate (0-10% residual tumor). Secondary endpoints are overall survival (OS), disease-free survival (DFS), objective response rate (ORR), and adverse events. Thirty resectable stage III–IVB HNSCC patients received sintilimab plus chemotherapy, followed by surgery and response-adapted PORT/POCRT. Patients with MPR received low-dose PORT (0–54 Gy), while patients without MPR received standard PORT/POCRT. The MPR rate was 59.1% (38.7%-76.7%). The MPR with low-dose group showed higher 2-year OS (100% vs. 77.8%) and DFS (100% vs. 55.6%) with fewer radiotherapy-related adverse events than non-MPR with standard-dose group (all P < 0.05). Adaptive radiation de-escalation maintains survival while reducing toxicity, representing a new strategy for LA-HNSCC. Neoadjuvant chemo-immunotherapy has emerged as a promising approach for locally advanced head and neck squamous cell carcinoma (HNSCC), but its implications for postoperative treatment remain uncertain. This phase 2 study reports efficacy outcomes of response-adapted postoperative therapy following sintilimab plus paclitaxel and cisplatin in patients with resectable HNSCC.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 30 de septiembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-77698-4